These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32139181)

  • 21. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V
    Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
    [No Abstract]   [Full Text] [Related]  

  • 22. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review.
    Nakum S; Cavanna AE
    Parkinsonism Relat Disord; 2016 Apr; 25():10-6. PubMed ID: 26923525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impulse control disorders associated with dopaminergic agonists in Parkinson's disease. Case report].
    Gamboa Arango A; Bernal Bernal MT; Duaso Magaña E
    Rev Esp Geriatr Gerontol; 2016; 51(5):304-5. PubMed ID: 27016028
    [No Abstract]   [Full Text] [Related]  

  • 25. Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease.
    Girard R; Obeso I; Thobois S; Park SA; Vidal T; Favre E; Ulla M; Broussolle E; Krack P; Durif F; Dreher JC
    Brain; 2019 Jan; 142(1):146-162. PubMed ID: 30590514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impulse control symptoms in patients with Parkinson's disease: The influence of dopaminergic agonist.
    Vargas AP; Vaz LS; Reuter A; Couto CM; Costa Cardoso FE
    Parkinsonism Relat Disord; 2019 Nov; 68():17-21. PubMed ID: 31621612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impulse control disorders in Parkinson's disease.
    Weintraub D; Potenza MN
    Curr Neurol Neurosci Rep; 2006 Jul; 6(4):302-6. PubMed ID: 16822350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical spectrum of impulse control disorders in Parkinson's disease.
    Weintraub D; David AS; Evans AH; Grant JE; Stacy M
    Mov Disord; 2015 Feb; 30(2):121-7. PubMed ID: 25370355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risky business of dopamine agonists in Parkinson disease and impulse control disorders.
    Claassen DO; van den Wildenberg WPM; Ridderinkhof KR; Jessup CK; Harrison MB; Wooten GF; Wylie SA
    Behav Neurosci; 2011 Aug; 125(4):492-500. PubMed ID: 21604834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinson's Disease.
    Choi JH; Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho JW
    Neurodegener Dis; 2019; 19(5-6):171-177. PubMed ID: 32454490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Impulsive-compulsive syndrome in Parkinson's disease].
    Nikitina AV; Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
    Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list.
    Fusaroli M; Raschi E; Contin M; Sambati L; Menchetti M; Fioritti A; Poluzzi E
    Parkinsonism Relat Disord; 2021 Sep; 90():79-83. PubMed ID: 34399162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Case Report.
    Luchsinger WT; Gambhir N; DeMoss D
    Prim Care Companion CNS Disord; 2018 Apr; 20(2):. PubMed ID: 29701928
    [No Abstract]   [Full Text] [Related]  

  • 36. Sex, drugs and Parkinson's disease.
    Ushe M; Perlmutter JS
    Brain; 2013 Feb; 136(Pt 2):371-3. PubMed ID: 23413258
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug-induced impulse control disorders: a review.
    Atmaca M
    Curr Clin Pharmacol; 2014 Feb; 9(1):70-4. PubMed ID: 24219002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
    Stocchi F; Vacca L; De Pandis MF; Barbato L; Valente M; Ruggieri S
    Neurol Sci; 2001 Feb; 22(1):93-4. PubMed ID: 11487217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Devotion to painting in a Parkinson's disease patient].
    Matsuda N; Kobayashi S; Ugawa Y
    Rinsho Shinkeigaku; 2018 Dec; 58(12):756-760. PubMed ID: 30487358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.